Dr Lars Gatenbeck, General Partner, is a founding partner of GZ Group and its two funds. Dr Gatenbeck is CEO of the fund advisors and oversees the strategic direction, life science sector focus and external relationships. He also devotes a large portion of his time to govern portfolio companies and support their CEOs. Currently he is chairman of the board of Cellavision AB and board member of Aerocrine AB and Profdoc ASA.

Dr Gatenbeck previously held leading positions in the European and US Pharmaceutical industry, a career including being Vice President of Pharmacia and Pharmacia Upjohn with global responsibility for several Therapy and Business Areas. Dr Gatenbeck has also been CEO and President of the Karolinska University Hospital in Stockholm, one of Europe's leading university hospitals. He has extensive experience of corporate governance as board member of several public and private companies in Europe. Public companies include Investment AB Öresund, Karo Bio, Pyrosequencing and Perbio Science.

Dr Gatenbeck has also a number of public assignments for the Swedish Medical and Biotech community including being a board member of Cancerföreningen and trustee of HM Gustav V anniversary fund, both cancer research foundations. He is also chairman of Invest in Sweden's life science initiative.

Dr Gatenbeck holds a MD and PhD from the Karolinska Institute, Stockholm.